SEC Form 4 · accession 0001493152-26-031890
LIXTE BIOTECHNOLOGY HOLDINGS, INC. · NMAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geordan Garrett Pursglove
Officer — CEO and Chairman of the Board · Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001335105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 1, 2026 | A | 350,000 | $0.00 | A | 700,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction involved the Reporting Person's receipt of 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.
- F2The total reported in Column 5 includes (i) the 350,000 newly awarded RSUs, and (ii) 350,000 RSUs, all of which have vested.